Loading
Total declarations
Company
▲ Purchases (21 ops.)
▼ Sales (0 ops.)
Latest filing published 23 Dec 2025 for Galectin Therapeutics INC, €17k. Read the official filing
Filing timeline
BuySaleKevin d. Freeman
Insider track record
Disclosed buys
21
Disclosed sells
0
T+90 hit rate
27%
T+90 mean return
-2.5%
Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Kevin d. Freeman: trading record in brief
This profile gathers the share dealings of Kevin d. Freeman in Galectin Therapeutics Inc, where the filings describe the role as board member. In total, 22 filings cover trades dated from 23 September 2021 to 23 December 2025.
On the market, this insider has only ever bought: 21 purchases, €204k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2025: 4 purchases and no sales on the market.
A typical purchase (the median) is worth €8,689. Of 18 purchases, 4 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The record was last updated on 23 December 2025 with an open-market purchase (€17k) in Galectin Therapeutics Inc. Typically, a trade is published a median of 3 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Kevin d. Freeman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations22 total
5,500 shares@ US$3.5488.1% of flowCommon StockSEC:0001133416-25-000080:0
Canonical exit: 23 Mar 2026 (T+90)
5,500 shares@ US$3.5488.1% of flowCommon StockSEC:0001133416-25-000075:0
Canonical exit: 23 Mar 2026 (T+90)
5,500 shares@ US$3.5488.1% of flowCommon StockSEC:0001133416-25-000081:0
Canonical exit: 23 Mar 2026 (T+90)
5,000 shares@ US$2.8998.1% of flowCommon StockSEC:0001133416-25-000033:0
Canonical exit: 15 Oct 2025 (T+90)
10,000 shares@ US$0.81343.6% of flowCommon StockSEC:0001133416-24-000062:0
Canonical exit: 24 Mar 2025 (T+90)
1,300 shares@ US$2.641.4% of flowCommon StockSEC:0001133416-24-000058:0
Canonical exit: 15 Jan 2025 (T+90)
5,000 shares@ US$2.705.7% of flowCommon StockSEC:0001133416-24-000056:0
Canonical exit: 14 Jan 2025 (T+90)
2,500 shares@ US$2.37992.5% of flowCommon StockSEC:0001133416-24-000044:0
Canonical exit: 18 Sept 2024 (T+90)
2,500 shares@ US$2.983.2% of flowCommon StockSEC:0001133416-24-000038:0
Canonical exit: 21 Jul 2024 (T+90)
2,063 shares0Common StockSEC:0001133416-24-000036:0
10,000 shares@ US$1.416.5% of flowCommon StockSEC:0001133416-22-000093:0
Canonical exit: 26 Jan 2023 (T+90)
5,000 shares@ US$1.32993.9% of flowCommon StockSEC:0001133416-22-000063:0
Canonical exit: 17 Aug 2022 (T+90)
5,000 shares@ US$1.714.9% of flowCommon StockSEC:0001133416-22-000057:0
Canonical exit: 17 Jul 2022 (T+90)
5,000 shares@ US$1.96120.0029% mcap5.1% of flowCommon StockSEC:0001133416-22-000010:0
Canonical exit: 19 Apr 2022 (T+90)
5,000 shares@ US$1.96125.3% of flowCommon StockSEC:0001133416-22-000008:0
Canonical exit: 19 Apr 2022 (T+90)
5,000 shares@ US$2.286.2% of flowCommon StockSEC:0001133416-21-000025:0
Canonical exit: 6 Mar 2022 (T+90)
5,000 shares@ US$2.286.2% of flowCommon StockSEC:0001133416-21-000027:0
Canonical exit: 15 Mar 2022 (T+90)
5,000 shares@ US$2.346.4% of flowCommon StockSEC:0001133416-21-000023:0
Canonical exit: 6 Mar 2022 (T+90)
2,000 shares@ US$3.173.3% of flowCommon StockSEC:0001133416-21-000017:0
Canonical exit: 27 Jan 2022 (T+90)
2,000 shares@ US$3.193.4% of flowCommon StockSEC:0001133416-21-000013:0
Canonical exit: 19 Jan 2022 (T+90)
3,000 shares@ US$3.36895.4% of flowCommon StockSEC:0001133416-21-000011:0
Canonical exit: 17 Jan 2022 (T+90)
3,000 shares@ US$3.8776.1% of flowCommon StockSEC:0001140361-21-032248:0
Canonical exit: 22 Dec 2021 (T+90)
22 of 22 declarations
